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Background: With the advent of highly active antiretroviral therapy (HAART), HIV infection has become a chronic
condition in children with improved survival and quality of life. Reports on long term effectiveness of non-nucleoside
reverse transcriptase inhibitor based HAART in HIV-infected children in developing countries are limited.
Methods: A chart review was conducted and children who received at least six months of HAART between 2004–2011
at All India Institute of Medical Sciences (AIIMS), Delhi were included. The clinical, immunological and virological
responses to HAART were documented. Factors predicting non-adherence and non-response to treatment were
described.
Results: One seventy five children (boys: 74.9%) were included in the study, with a median follow up of 43 (IQR:17, 68)
months. The median age at diagnosis was 119 (IQR: 75, 156) months. The median CD4 count at start of HAART was 340
cells/μL (IQR: 185,704), which increased to 924 cells/μL (IQR:591,1278) at 48 months after HAART and plateaued at
749 (IQR: 542,1056) cells/ μL after 90 months of therapy. The weight for age (WAZ) and height for age (HAZ) z score
both showed improvement with time after HAART initiation [baseline: WAZ −2.8 (IQR:-4,-1.6), HAZ −2.1 (IQR:-3.4,-0.69);
at 42 months of therapy: WAZ −1.2 (IQR:-2.1, 0.01), HAZ −0.75(IQR:-1.6,-0.37)]. Adverse events were reported in 21 (12%)
children. Non-adherence to therapy, treatment failure and death were noted in 35 (20%), 9 (5.1%) and 6 (3.4%) children
respectively.
Conclusions: Our experience shows that HAART in HIV-infected children is effective, safe and is associated with good
immunological and virological response as well as improvement in growth parameters.
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Highly active anti-retroviral therapy (HAART) has
been reported to be efficacious in terms of hastening
immunological recovery and enhancing growth in HIV-
infected children across the world. Survival has greatly
improved with the advent of HAART in children. There
are reports of positive influence of HAART on the overall
quality of life of children living with HIV/AIDS [1-7].
There is paucity of studies reporting long term outcomes
in children receiving non-nucleoside reverse transcriptase
inhibitor (NNRTI) based HAART. Recently Phongsamart
et al. have reported the long term outcomes in Thai HIV-
infected children receiving ART; the median follow up
was 2.9 years [8]. The authors concluded that immune* Correspondence: rakesh_lodha@hotmail.com
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unless otherwise stated.reconstitution occurred in nearly 80% children. In a retro-
spective analysis of data, after 24 months of HAART, one
in three children was likely to develop treatment failure
[9]. In the ARROW trial, excellent outcomes were repor-
ted in children receiving NNRTI based or 3NRTI based
regimen [10].
There is paucity of reports of long-term outcomes in
HIV- infected children receiving NNRTI based regimen
from Indian sub-continent. We report here the experience
with use of HAART in HIV infected children who have
been on long term follow up in an Indian center.Methods
We conducted a review of case records of HIV- in-
fected children who received HAART in the Department
of Pediatrics, All India Institute of Medical Sciences,
Delhi, between 2004 to 2011. The study protocol of thistral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Committee (Ref No IEC/NP-354/2013). As this was a
retrospective review of information in the case records,
informed consent was not taken.
Inclusion criteria
HIV-infected children, 1–15 years of age, who had
received HAART for at least 6 months were included.
Diagnosis
HIV infection was confirmed using three sets of Enzyme
immunoassays (EIA) test for HIV-1 according to National
AIDS Control Organization (NACO) guidelines [11-13].
In children less than 18 months age, diagnosis of HIV in-
fection was made on the basis of two positive HIV-DNA
PCR tests [13].
The routine diagnostic work-up for all patients included
blood tests for serum biochemistry (renal and liver func-
tion tests), complete hemogram, CD4 cell count for all
and also CD4 percentage for children ≤ 5 years. The CD4
was measured by flow cytometry (BD FACS Caliber, San
Diego, USA). HIV RNA viral load was available for some
subjects at different points of follow-up. Viral load estima-
tion was done by real time PCR (COBAS TaqMan, Roche
Diagnostics, Indiana, USA); the lower limit for detection
was 47 copies/mL.
Based on clinical profile, a targeted search for an oppor-
tunistic infection was performed. Clinical and immuno-
logical stage was assigned to HIV children based upon the
WHO clinical and immunological criteria for HIV staging
[13]. Indications to start antiretroviral therapy were based
on available guidelines [13-15].
Treatment regime
The preferred first line antiretroviral drugs were combin-
ation of 2 nucleoside reverse transcriptase inhibitors
(NRTI) + 1 non-nucleoside reverse transcriptase inhibitor
(NNRTI): zidovudine(AZT) + lamivudine (3TC) + nevira-
pine (NVP) or efavirenz (EFV) or stavudine(d4T) + 3TC +
NVP or EFV. In patients with HIV-TB co-infection, efavir-
enz based regimen was preferred in children > 3 years in
view of interaction between nevirapine and rifampicin; in
children below three years of age nevirapine was con-
tinued with rifampicin. Co- trimoxazole prophylaxis was
administered according to available guidelines [13].
Follow-up and monitoring
All the patients were followed every 3 months. During
each follow up visit, weight and height were recorded,
adherence to treatment was checked, symptoms were
noted, physical examination was done, and side effects
were recorded. Complete blood count, serum chemistry
and CD4 counts were monitored every 6 months. Ad-
herence to treatment was monitored by interviewing thechild/guardian at each visit and by pill count. Non-
adherence was defined as missing of three or more doses
in a period of 30 days.
Data collection
Data from the patients’ clinical records (obtained from
the pediatric OPD medical record room) were recorded
in the structured sheets and entered in the Microsoft
Access 2010 to form an electronic database. A retro-
spective data auditing was performed to ensure accuracy.
The primary outcomes of interest in this study were re-
sponse to HAART in terms of immunological and clin-
ical response, all cause mortality rate and treatment
failure. The treatment failure was defined as per NACO
guidelines [13]. Clinical failure was defined as the ap-
pearance or reappearance of WHO clinical stage 3 or
stage 4 events after at least 24 weeks on HAART in a
treatment-adherent child. Immunological failure was de-
fined as developing or returning to the following age-
related immunological thresholds after at least 24 weeks
on HAART, in a treatment-adherent child:
 CD4 count of <200 cells/mm3 or %CD4 <10 for a
child ≥2 years to <5 years of age
 CD4 count of <100 cells/mm3 for a child 5 years of
age or older.
Virological failure was defined as a persistent viral load
above 5000 RNA copies/mL on two consecutive mea-
surements, after at least 24 weeks on HAART, in a
treatment-adherent child. Death was ascertained either
from the hospital records or from the telephonic conver-
sation with the relatives. The clinical response to HAART
was determined by decrease in the number of episodes of
illness. Immunological response was based on the CD4
values at different time points. The secondary outcomes
assessed were change in anthropometric values in terms
of z scores at different time points and changes in blood
parameters i.e. hemoglobin, erythrocyte sedimentation
rate (ESR) over time. We also attempted to determine the
factors associated with non-adherence and treatment
failure.
Statistical methods
The electronic data were exported into the Stata soft-
ware, version 9.0 (StataCorp, College Station, TX, USA)
for statistical analysis. The z scores for weight for age
and height for age were calculated using the statistical
package EPI-INFO 2000 (Centers for Disease Control
and Prevention, USA). Logistic regression model was used
to determine the factors responsible for non-adherence
and also non-response to treatment. A generalized esti-
mating equation model was tested to look into the associ-
ation between average change of CD4 count over 48 month
Table 1 Baseline characteristics (clinical and demographic)
Characteristics Values
Age (median, IQR) 119 (75–156) months
Boys 131 (74.9)
Lost one parent 71 (40.5)
Lost both parents 33 (18.9)
Age at diagnosis (median, IQR) 58 (29,96) months
Mode of transmission
Perinatal 142 (81.2)
Blood transfusion 6 (3.4)
Uncertain 27 (15.4)










WAZ before starting HAART
≥−2 z 136 (77.7)
< −2 to> −3 14 (8)
≤−3 29 (14.3)
HAZ before starting HAART
≥−2 z 148 (84.6)
< −2 to> −3 9 (5.1)
≤−3 18 (10.3)
Received BCG 109 (62.3)
History of contact with TB 60 (34.3 )
TB disease diagnosed before initiating HAART 47 (26.9 )
TB developed after initiating HAART 15 (8.6)
All values are n (%) unless specified. IQR: interquartile range, WHO: World
Health Organization, WAZ: weight for age z score, HAZ : height for age z score,
BCG: Bacillus Calmette Guerin, HAART: highly active anti-retroviral therapy,
TB: tuberculosis.
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and average change of anthropometric parameters.
Results
We screened records of 400 children; 175 children met
the study criteria; these children had received HAART for
atleast 6 months. The median (IQR) duration of follow up
was 43 (IQR: 17, 68) months. Since 2005, six (3.4%) chil-
dren died after initiating HAART and 20 (11.4%) children
were lost to follow up. The median interval between
initiation of HAART and death/ lost to follow up was 24
(IQR: 12,24) months.
Baseline characteristics
The baseline characteristics of patients on HAART are
mentioned in Table 1. The median age at diagnosis was
119 months (IQR: 75,156 months) and there was a
predominance of boys (74.9%).
At diagnosis, the most common clinical presentations
were recurrent fever (87 children, 49.7%) and failure to
thrive (70 children, 40%). Only 15% of HIV-infected
children, who were subsequently initiated on HAART,
were asymptomatic at presentation. Tuberculosis (47 chil-
dren) was the most common opportunistic infection (OI)
in these patients before starting HAART. After starting
HAART, 15 (8.6%) children developed tuberculosis. Diag-
nosis of TB was clinico-radiological. AFB/ Mycobacterium
tuberculosis was positive in eight children before starting
HAART and only one child after starting HAART. Other
OIs observed before starting HAART were cryptosporidi-
osis (4 children), Herpes simplex (7 children), candidiasis
(4 children), Isospora belli (1 children) and Cytomegalo-
virus (2 children) infection.
Table 2 shows the immunological, virological and
treatment parameters at the initiation of HAART. The
median CD4 count at start of HAART was 340 cells/μL
(IQR: 185, 704).
Response to anti-retroviral therapy: There was improve-
ment in clinical symptoms with a decline in the number
of episodes of clinical events after starting HAART. The
number of episodes of upper respiratory tract infection
over 6 months reduced from 5.5 events per 100 child-
months in the first six months after starting HAART to
2.9 events per 100 child-months after 48 months of
therapy. Similarly incidence of lower respiratory tract
infections declined from 3.3 events per 100 child-months
in the first six months after initiation of HAART to 1.4
events per 100 child-months at 48 months of therapy,
febrile episodes due to any cause decreased from 3.9 to
2.1 events per 100 child-months. There was no significant
difference in incidence of events like thrush, herpes infec-
tion or seizures (data not shown).
There was good immunological and virological response
to HAART. The median CD4 count increased from 340cells/μL (IQR: 185,704) at initiation to 924 cells/μL (IQR:
591,1278) at 48 months after HAART (p < 0.001) and
remained at 749 (IQR: 542, 1056) calls/ μL after 90 months
of therapy. Figure 1 shows the trend in CD4 count from
baseline to 48 months after HAART. The median CD4
count gradually peaked at 18 months post HAART and
maintained a plateau thereafter upto 48 months. For chil-
dren diagnosed before five years of age, the median CD4
percentage increased from 13% (IQR: 8.4, 21) at baseline
to 29.3% (IQR: 19, 31) 48 months after initiation of
HAART, p = 0.02. Viral load was available in 76 children.
After a median duration of 34.4 months (IQR: 10.4, 47) of
Table 2 Immunological and treatment parameters at the
initiation of therapy
Parameter Values
Duration of follow up while on
HAART, months, median (IQR)
43 (17,68)
CD4 count, cells/μL, median (IQR) 340 (185,704)
Age <2 years (n = 27) 424 (304,729)
Age 2-5years (n = 20) 460 (260,871)
Age >5 years (n = 128) 288 (163,639)
CD4%, mean (SD) 13.3 (10.7)






HIV: human immunodeficiency virus, HAART: highly active
anti-retroviral therapy.
d4T: stavudine, 3TC: lamivudine, AZT: zidovudine, NVP: nevirapine,
EFV: efavirenz.
Figure 2 Changes of weight for age (WAZ) and height for age
(HAZ) z‐ scores over 48 months from the initiation of HAART.
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47, 958)RNA copies/mL; 49 (66%) children had undetect-
able viral load.
Anthropometric measures too showed improvement
over time. The median WAZ changed from −2.8
(IQR: −4,-1.6) at the start of therapy to −1.2 (IQR: −2.1,
0.01) at 42 months post initiation of HAART, p = 0.04
(Figure 2). Median HAZ changed from −2.1 (IQR: −3.4,-
0.69) at initiation to −0.75 (IQR:-1.6,-0.37) after 42 months
of HAART, p = 0.04 (Figure 2). There were changes in the
hematological parameters like hemoglobin and ESR in
response to HAART. The mean (SD) hemoglobin in-
creased from 9.3 (1.9) g/dL at baseline to 12.9 (1.3) g/dL
at 84 months post HAART, p = 0.003; whereas ESR
decreased from the mean (SD) of 41.9 (25) mm in 1sthr to
27.6 (17.1) mm in 1st hr at 84 months of HAART, p = 0.1.Figure 1 Change in median CD4 count (cells/μL) with IQR over
48 months of HAART.It was observed that the overall average change in
CD4 count over 48 months of therapy did not have any
significant association with the average change in weight
for age and height for age z-scores. However, the average
change in CD4 count was significantly associated with
gender (p = 0.02), being more in female gender and also
with age at diagnosis – the change being more for youn-
ger age at diagnosis (p = 0.02).
Predictors of response to anti-retroviral therapy
Most of the children (94.9%) in this cohort responded
well to HAART. Overall only 9 (5.1%) children were
suspected of having treatment failure, of which clinical
failure was seen in 4 children, immunological failure in 2
children and virological failure in 3 children. The me-
dian time to treatment failure from initiation of HAART
was 43 (IQR: 18, 54) months. In a logistic regression
model, treatment failure could not be predicted by fac-
tors like age at diagnosis, gender, initial CD4 count and
duration of HAART (Table 3).
Therapy was scaled up to second line antiretroviral
therapy due to treatment failure in four children.
Adherence
The total number of children who were non-adherent to
therapy was 35 (20%). The mean (SD) age of the chil-
dren who were non-adherent was 150.7 (53.1) months,
with 82.7% (29) of them being boys. A logistic regression
analysis was done to determine the factors predictingTable 3 Predictors of treatment failure, by logistic
regression model
Characteristics Odds ratio (95% CI)
Male gender 0.64 (0.07 – 6.16)
Age at diagnosis, months 0.99 (0.98 – 1.0)
CD4 count at initiation of HAART 0.99 (0.99 – 1.0)
Duration of HAART, months 1.01 (0.99 – 1.03)
HAART: highly active anti-retroviral therapy.
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gender, clinical stage of disease at diagnosis, whether par-
ents are alive or not and duration of HAART; it was
observed that the older the child more the chances of
non-adherence (OR = 1.02, 95% CI: 1.004, 1.03, p = 0.008)
and also there was a trend towards more chances of non-
adherence in case the father of the child had expired
(p = 0.06) as compared to children whose father was alive,
irrespective of whether mother was alive or not.
Adverse events
Adverse events were noted in 21 (12%) children. The
adverse events observed during the follow up visits were
pancreatitis due to stavudine (1 child), rash due to nevi-
rapine (4 children), lipodystrophy due to stavudine (5
children), anemia due to zidovudine (6 children), hepa-
titis (4 children) and peripheral neuropathy (1 child).
Antiretroviral treatment had to be changed in 20 chil-
dren because of adverse events or tuberculosis. Treat-
ment was changed from nevirapine based to efavirenz
based regimen in 9 children (7 due to starting of antitu-
bercular therapy, 2 due to NVP sensitivity), stavudine to
zidovudine based regimen in 3 children (2 due to lipody-
strophy, 1 due to pancreatitis), zidovudine to stavudine
based therapy regimen in 8 children (6 due to anemia, 2
due to availability issues). The median time of changing
of regime from initiation of HAART was 8 (IQR: 4, 22)
months.
Discussion
This cohort of 175 children gives us a good insight into
the clinical and immunological characteristics of HIV-
infected Indian children at the initiation of HAART and
their response to treatment. The early diagnosis of chil-
dren with HIV infection is imperative to initiate HAART
before significant immunological compromise occurs
[1,16]. In our study, the children had a delayed presenta-
tion and more than half of HIV-infected children (57%)
presented with severe immunological compromise. Re-
source limited settings seem to share this experience as
seen in earlier Indian and African studies [3,17,18]. More
stress on early diagnosis and encouragement of early
health seeking behavior is necessary for a successful
campaign against HIV-AIDS.
In this cohort of children, a large proportion (74.9%)
were boys. In our setting the male: female disparity is
commonly seen for most disease conditions suggesting a
gender bias in health care seeking behaviors of the popu-
lation [19].
After initiation of HAART, there was overall good
immunological response with CD4 count more than
doubled at 18 months post HAART. Similar immuno-
logical recovery both temporally and quantitatively has
been reported by other studies [8-10,18]. The sustainedimmunologic improvement in terms of CD4 count at least
till 7 years after initiation of therapy, has also been re-
ported from other long term follow-up study in children
[20]. The viral load and ‘z’ scores for weight and height for
age also improved with time in our study. Mulu et al.
reported virological suppression in 87% children receiving
HAART for a median of 24 months [21]. Patel et al. re-
ported similar effects of protease inhibitor (PI) based
HAART and NNRTI based HAART in children followed
up for a median of 1 year [22].
There was an improvement in the overall clinical sta-
tus of the children with fewer numbers of episodes of
acute infections with time. This has been described in
other studies in children [2,4].
About five percent of our children were categorized as
treatment failure based on clinical, immunological or
virological criteria. Recent estimates of treatment failure
and requirement of 2nd line HAART in low and middle
income countries is around 3% [23]. The mean time to
treatment failure in our study was found to be longer
than the time to treatment failure reported in other
studies [24]. Also, in contrast to the study by Bachaet al,
treatment failure in our study was independent of the
predictors like age at diagnosis, gender, initial CD4
count and duration of HAART [24]. The CD4 count
trajectory was significantly associated with gender and
age in our study. Female children showed better CD4
recovery compared to male children. Study conducted
by Barry O et al., in Ghana reported similar finding of
correlation between CD4 trajectory and gender [25].
In terms of safety, the antiretroviral therapy used in
our children was safe with few adverse effects observed.
Self-reported adherence was about 80% in our patients
as well as in other studies from India and Africa [26,27].
Non-adherence in our children was associated with age
of the child and death of father. Other studies probing
into the correlates of adherence in an Indian setting have
found orphanhood, longer duration of therapy to be
amongst the factors predicting poor adherence [27].
Predictors of response to treatment include: age at ini-
tiation, immune status and viral load at time of initiation
[22]. Ensuring excellent adherence to the HAART regi-
men is also crucial for ensuring long term effectiveness
of HAART regimen. An adherence indicator based on
timeliness of clinic attendance has been shown to strongly
predict both virological response and drug resistance; the
authors conclude that this indicator could help to timely
identify non-adherent patients in settings where viral load
monitoring is not available [28].
Globally, over the years, there has been tremendous
progress in diagnosing and treating infants and children
with HIV infection. However, in many low resource set-
tings, the diagnosis and treatment of children with HIV
infection still remains a challenge. The reasons for this
Mukherjee et al. BMC Infectious Diseases  (2014) 14:701 Page 6 of 7vary from lack of technical expertise to inadequate avail-
ability of resources. Viral load is an important parameter
for monitoring treatment response. There should be
provision in the national guidelines to provide laboratory
facilities for viral load testing to monitor the treatment
response and also to detect the treatment failure.
The limitation of the study is that the causal associ-
ation between CD4 count, viral load and other clinical
parameters and overall treatment response cannot be
accurately determined due to the retrospective nature of
the study. Also, the viral load studies were not available
for all the patients in our study. So, we could not accur-
ately comment on the virological response and virological
failure.
The strengths of our study lie in the large number of
children followed up along with the long duration of
follow-up of upto seven years.
Conclusions
Our experience shows that NNRTI-based HAART in
HIV-infected children is effective, safe and is associated
with good immunological and virological response as
well as improvement in growth parameters over a long
term.
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